Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?

Nature Clinical Practice Oncology volume 5, pages 14–15 (2008)Cite this article

boxed-textHehlmann R et al. (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109: 4686–4692

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Goldman JM and Druker BJ (2001) Chronic myeloid leukemia: current treatment options. Blood 98: 2039–2042

    Article  CAS  Google Scholar 

  2. Gale RP et al. (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 91: 1810–1819

    CAS  PubMed  Google Scholar 

  3. Ohnishi K et al. (2004) Multicenter prospective study of interferon alpha versus allogeneic stem cell transplantation for patients with new diagnoses of chronic myelogenous leukemia. Int J Hematol 79: 345–353

    Article  CAS  Google Scholar 

  4. Druker BJ et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408–2417

    Article  CAS  Google Scholar 

  5. Schmitz N et al. (2006) Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108: 4288–4290

    Article  CAS  Google Scholar 

  6. Simonsson B, on behalf of the ISG (2005) Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): update from the IRIS Study [abstract]. ASH Annual Meeting Abstracts 106: 166a

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Eleftheria Rosmaraki, Assistant Editor, Nature Clinical Practice.

Author information

Author notes

  1. Division of Hematology, Institute of Medical Veterinary Science, Frome Road, Adelaide, SA 5000, Australia timothy.hughes@imvs.sa.gov.au

Authors and Affiliations

  1. T Hughes is a Clinical Professor at the University of Adelaide and Deputy Head of the Division of Hematology at the Institute of Medical and Veterinary Science, Adelaide, Australia.,

    Timothy Hughes

Authors
  1. Timothy Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

T Hughes has received honoraria for lectures, and is recipient of clinical research support from BMS and Novartis. Dr Hughes is a patent holder for Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hughes, T. Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?. Nat Rev Clin Oncol 5, 14–15 (2008). https://doi.org/10.1038/ncponc0983

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0983

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing